Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
Neurocrine Biosciences Announces Key Leadership Hiring, Promotions
04:05pm, Thursday, 23'rd Jul 2026
SAN DIEGO, July 23, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of three Senior Vice Presidents, further strengthening its leadership team as the
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:01am, Thursday, 23'rd Jul 2026
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
California Public Employees Retirement System Purchases 25,620 Shares of Neurocrine Biosciences, Inc. $NBIX
04:17am, Wednesday, 22'nd Jul 2026
California Public Employees Retirement System raised its position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 13.0% in the undefined quarter, according to the company in its most recen
Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer
04:05pm, Tuesday, 21'st Jul 2026
SAN DIEGO, July 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Samir Siddhanti as Chief Business Officer and a member of the company's executi
NVIDIA & 2 Best Earnings Growth Stocks to Buy for 2H 2026
04:00pm, Wednesday, 15'th Jul 2026
NVIDIA, Neurocrine and Ball screen well for earnings growth and rising estimates, highlighting stocks with improving profit expectations.
Can Neurocrine (NBIX) Run Higher on Rising Earnings Estimates?
01:21pm, Tuesday, 14'th Jul 2026
Neurocrine Biosciences (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)
01:46pm, Friday, 10'th Jul 2026
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline
11:58am, Friday, 10'th Jul 2026
Biopharmaceutical firm Neurocrine Biosciences, Inc. (NBIX) up over 35% in a year and 17% since outlier inflows in May.
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
04:01pm, Thursday, 09'th Jul 2026
Conference Call and Webcast Scheduled for Thursday, July 30 SAN DIEGO, July 9, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter
Why Crinetics Stock Soared 99% This Week
01:29pm, Thursday, 09'th Jul 2026
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.
Neurocrine (NBIX) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:01pm, Wednesday, 08'th Jul 2026
Neurocrine (NBIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Reasons Why Investors Should Consider Betting on Neurocrine Stock
11:45am, Monday, 06'th Jul 2026
NBIX builds on Ingrezza's momentum with pipeline advances and the Soleno acquisition, strengthening its long-term neuroscience growth strategy.
Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno
02:55pm, Thursday, 02'nd Jul 2026
Neurocrine Biosciences, Inc. remains a Buy, driven by robust growth from Ingrezza, Crenessity, and the recent Vykat acquisition. Q1 2026 revenues rose 44% year-on-year to $811m, with Ingrezza and Cren
SAN DIEGO, July 1, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont
Neurocrine Biosciences (NBIX) Is Up 6.46% in One Week: What You Should Know
01:01pm, Wednesday, 01'st Jul 2026
Does Neurocrine Biosciences (NBIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
